CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$56.09 USD
-0.17 (-0.30%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $56.05 -0.04 (-0.07%) 7:58 PM ET
5-Strong Sell of 5 5
F Value B Growth B Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRSP 56.09 -0.17(-0.30%)
Will CRSP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
New Strong Sell Stocks for August 1st
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
Should You Invest in CRISPR Therapeutics (CRSP) Based on Bullish Wall Street Views?
Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know
Other News for CRSP
Cathie Wood Loads Up Millions on Google, AMD in Bold ARK Shift
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics
Undercovered Dozen: Power Solutions, Porsche, B2Gold And More
Cathie Wood Doesn't Need Tesla To Win—ARKK Delivers A Blowout While EV Giant Idles
CRSP September 5th Options Begin Trading